Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-10-22Est. Completion: 2028-02
Enrollment target: 40 participants
Locations
University Hospital Augsburg, II. Medizinischen Klinik, Hämatologie, internistische Onkologie und Hämostaseologie, Augsburg, Germany
Charité Berlin, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumorimmunologyt Hämatologie, Berlin, Germany
Gesundheit Nord Klinikverbund Bremen gGmbH, Klinikum Bremen-Mitte, Med. Klinik I, Bremen, Germany
Klinikum Carl Gustav Carus Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany
University Hospital Düsseldorf, Department of Hematology, Oncology and Clinical Immunology, Düsseldorf, Germany
University Hospital Erlangen AöR, Department of Medicine 5, Erlangen, Germany
Goethe University Hospital Frankfurt, Department of Medicine, Hematology and Oncology, Frankfurt am Main, Germany
University Hospital Hamburg-Eppendorf, Department of Medicine II, Hamburg, Germany
University Hospital Heidelberg, Department V, Hematology, Oncology and Rheumatology, Heidelberg, Germany
University Hospital Schleswig-Holstein, Campus Kiel, Medical Department II, Kiel, Germany
University Hospital Leipzig; Klinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie, Bereich Hämatologie und Zelltherapie, Leipzig, Germany
Other microbiome trials you might be interested in
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK)…
El Paso, United StatesEst. completion Jul 10, 2028